Researchers may have identified imaging-based biomarkers that could be used to identify different subtypes of major depressive disorder (MDD) and potentially lead to the d
Swedish medtech start-up Capitainer has started working with AstraZeneca on a project to use a device for sampling cell-free blood in clinical trial programmes.
Three years after it started working with Pfizer, artificial intelligence-powered drug discovery specialist CytoReason has converted the relationship into a lucrative, wide-ranging contract
Neurodegenerative diseases like Parkinson’s and Alzheimer’s affect millions of people worldwide, and their prevalence is only increasing, according to the World Health Organization.
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho